Gurpreet has deep expertise in biotechnology, from both an investment banking perspective and from a drug development perspective. As a biotechnology equity analyst, Gurpreet was involved in the analysis and valuation of small and mid-cap companies in several therapeutic areas including HCV, metabolic and autoimmune diseases, cancer, stem cells and diagnostics.

Gurpreet also has several years of experience in preclinical drug development strategies including study design for pharmacologic and toxicologic evaluation, data examination and preparation of reports for FDA submissions. He started his career as a post-doctoral research fellow at UC Berkeley, and has published papers in the fields of drug action and safety. He has also acted as a consultant to the biotechnology and venture capital industries.

Gurpreet has a PhD in pharmacology & toxicology from St. Bartholomew’s Medical School, University of London with an expertise in drug-induced mechanisms of hepatic injury, and an MBA from Haas School of Business at UC Berkeley, with a focus on finance, technology assessment and venture capital.